THIS APPLICATION IS FOR HEALTHCARE PROFESSIONALS ONLY.
Date of preparation: January 2013
Job Item: PHGB/VEL/0113/0018
Developed by Janssen, the Velcade® Dose modification app has three functions; a Dose Calculator a Dose Modification Calculator and also information on the appropriate administration and reconstitution of Velcade intravenous (IV) and Subcutaneous (SC).
Dose Calculator
This interactive application assists a healthcare professional to calculate a patients’ dose for their Velcade® treatment. This tool will generate the dosing for the patient at 1.3 mg/m2, 1.0 mg/m2 and 0.7 mg/m2 allowing the healthcare professional to start or adjust the dosing regimen appropriately. Any dose modifications should be made with an understanding of how to manage treatment related side effects.
Dose Modification Calculator
The healthcare professional will be asked some simple diagnostic questions to help the application calculate the dose adjustment for the patient as recommended in the SmPC. Working through the necessary steps using the ‘Dose Modification Calculator’ will provide information from the SmPC on how to manage patients’ treatment related side effects effectively.
Administration and Reconstitution section
In order to avoid dosing errors, caution is required when administering VELCADE via the SC route as the volume required for reconstitution is lower (1.4ml) than that used for IV use (3.5ml) giving a higher concentration of diluted drug.
This section provides the appropriate information on the correct administration and reconstitution of Velcade intravenous (IV) and Subcutaneous (SC). It also provides dosing examples.
Link to the prescribing information and the SmPC can be found throughout the app and can also be viewed here http://www.medicines.org.uk/guides/velcade/myeloma
This App is not a medical device. The App and the information generated from it should not be used as a basis for any diagnosis, monitoring, management or treatment. The App is intended for use as an educational tool. Any calculations should be verified using traditional scoring techniques and clinical judgment.
Adverse events should be reported and information can be found at http://www.mhra.gov.uk/yellowcard. Adverse reactions should also be reported to Janssen- Cilag Ltd on 01494 567447.
Please help us by not talking directly about specific drugs or named medicines. Please use the review section to comment on the app only. Report all adverse events using the contact details above. All non healthcare professionals who would like more information about Velcade® should visit www.janssen.co.uk and select the relevant link.